Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday. Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday. Lipfendra blocks the action of PCSK9, a naturally occurring protein that affects how the liver removes LDL ("bad") cholesterol from the bloodstream. DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN 'JUMPSTART' BETTER HEALTH "PCSK-9 is a protein that works in the liver, preventing the recycling of LDL receptors, as a result increasing bad cholesterol i